Back to News
Jan 9, 2026 4:00 AM

Merck In Talks To Buy Cancer Drug-Maker Revolution Medicines In A $28 To $32 Billion Deal — Stock Soars Overnight

Pharmaceuticals giant Merck & Co. Inc. (NYSE:MRK) is reportedly in talks to acquire cancer drug-maker Revolution Medicines Inc. (NASDAQ:RVMD) in a deal potentially valued at between $28 and $32 billion.

Shares of Revolution Medicines were up 4.56% on Thursday, before soaring 15.14% overnight after the news broke out, now trading at $123.65 per share.

Merck On A Buying Spree

The deal is yet to be finalized and any potential tie-ups are weeks away, according to a report by the Financial Times citing sources familiar with the matter.

If it goes through, the deal is set to become the largest transaction in the biotech space since Pfizer Inc.’s (NYSE: